[8-K] Mammoth Energy Services, Inc. Reports Material Event

Rhea-AI Filing Summary

Crinetics Pharmaceuticals, Inc. (CRNX) filed a Form 8-K under Item 7.01 (Regulation FD). The filing discloses that the company issued a press release announcing eight scientific abstracts from its endocrine and rare-disease pipeline that will be presented at the Endocrine Society’s Annual Meeting (ENDO 2025) in San Francisco, July 12-15, 2025.

The abstracts will cover development candidates atumelnant (ACTH antagonist), paltusotine (oral SST2 agonist), and the TSHR antagonist CRN12755. The company also reiterates plans for the potential commercial launch of PALSONIFY (commercial name for paltusotine) if regulatory approval is obtained.

No new clinical data, financial figures, or transaction details are provided in the 8-K; the disclosure is limited to notification of the upcoming presentations. All forward-looking statements are qualified by customary risk factors, including clinical, regulatory, and geopolitical uncertainties.

Positive

• Eight abstracts accepted for ENDO 2025, demonstrating breadth and continued progress across multiple endocrine programs.
• Multiple pipeline candidates highlighted (atumelnant, paltusotine, CRN12755), keeping investor attention on diversified clinical assets.

Negative

• No new clinical or financial data were disclosed, limiting immediate valuation impact.
• Forward-looking statements emphasize numerous development and regulatory risks without providing mitigating updates.

Insights

Biotech Equity Analyst

TL;DR – Pipeline visibility rises, but no new data; limited market impact.

The 8-K merely alerts investors to forthcoming scientific presentations. While announcing eight abstracts does signal an active R&D engine spanning atumelnant, paltusotine, and a TSHR antagonist, the lack of fresh efficacy or safety readouts keeps valuation unchanged for now. Investors will look to ENDO 2025 data for potential inflection points, particularly around paltusotine’s commercial readiness and CRN12755’s first-in-human progress. Absent those results, today’s filing is informational and non-material.

Risk Analyst

TL;DR – Disclosure highlights standard development risks; impact neutral.

The company reiterates numerous forward-looking statements and risk factors common to clinical-stage biopharma: trial timing, regulatory review, supply-chain disruption, and data variability. Because no new commitments or financial obligations arise from the ENDO 2025 participation, downside or upside risk profile is unchanged.

0001679268FALSE00016792682025-06-242025-06-24

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): June 24, 2025

Mammoth Energy Services, Inc.

(Exact name of registrant as specified in its charter)

001-37917

(Commission File No.)

Delaware

32-0498321

(State or other jurisdiction of incorporation or organization)

(I.R.S. Employer Identification No.)

14201 Caliber Drive,

Suite 300

Oklahoma City,

Oklahoma

(405)

608-6007

73134

(Address of principal executive offices)

(Registrant’s telephone number, including area code)

(Zip Code)

______________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of The Act:
Title of each class			Trading Symbol(s)			Name of each exchange on which registered
Common Stock			TUSK			The Nasdaq Stock Market LLC
						NASDAQ Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§232.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging Growth Company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(s) of the Exchange Act.  ¨

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On June 24, 2025, the Mammoth Energy Services, Inc. (the “Company”) board of directors (the “Board”) appointed Phil Lancaster as a non-independent voting member of the Board effective July 1, 2025. Mr. Lancaster is currently the Company’s Chief Executive Officer (“CEO”). As previously announced in the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission (“SEC”) on June 5, 2025, Mr. Lancaster resigned from his CEO position effective June 30, 2025. Mr. Lancaster’s full biography is included in the Company’s definitive proxy statement on Schedule 14A, filed by the Company with the SEC on April 28, 2025, and is incorporated into this Item 5.02 by reference.

In connection with Mr. Lancaster’s appointment to the Board, he is entitled to receive the annual compensation generally given to the Company’s non-employee directors for his services on the Board (prorated for the dates of service). The Company’s non-employee directors are entitled to receive an annual retainer in the amount of $50,000, plus a payment of $5,000 for each meeting attended over the four regularly scheduled meetings per year.

Also on June 24, 2025, the Board determined Arthur Amron, the chairman of the Board, meets the standards regarding independence set forth in the Nasdaq listing standards and is free of any relationship which, in the opinion of the Board, would interfere with the exercise of independent judgment in carrying out his responsibilities as a director of the Company. As such, effective July 1, 2025, four of the Company’s six directors, comprising the majority of the Board, meet the independence standards.

Signature

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

MAMMOTH ENERGY SERVICES, INC.

Date:

June 30, 2025

By:

/s/ Mark Layton

Mark Layton

Chief Financial Officer and Secretary

FAQ

When will Crinetics (CRNX) present its ENDO 2025 abstracts?

The presentations are scheduled for July 12-15, 2025, at the Endocrine Society’s annual meeting in San Francisco.

How many abstracts is Crinetics presenting at ENDO 2025?

The company will present eight abstracts covering several pipeline programs.

Which pipeline programs are included in the ENDO 2025 abstracts?

Abstracts will feature atumelnant, paltusotine, and the TSHR antagonist CRN12755.

Does the 8-K contain new clinical results for paltusotine or atumelnant?

No. The filing only announces upcoming presentations and contains no new efficacy or safety data.

What is PALSONIFY mentioned in the filing?

PALSONIFY is the proposed commercial name for paltusotine, which Crinetics plans to launch if regulatory approval is granted.